What's Happening?
Cepheid, a leader in molecular diagnostics, and Oxford Nanopore Technologies have announced an expansion of their partnership to develop a workflow for rapid identification of bacterial and fungal pathogens. This collaboration follows a successful phase
one, which was introduced at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025. The new phase aims to enhance pathogen identification, antimicrobial resistance profiling, and genomic antibiotic susceptibility testing for bloodstream infection and sepsis research. The updated workflow will be available for research use only and is expected to be accessible to several leading physician-scientists by Q3-2026. The companies aim to make advanced infectious disease research more practical and widely achievable by leveraging Cepheid's GeneXpert platform and Oxford Nanopore's sequencing technology.
Why It's Important?
The expansion of this partnership is significant as it promises to improve the speed and accuracy of infectious disease research, which is crucial for public health. Rapid genomic testing can lead to better patient care by enabling prompt and accurate predictions of antibiotic resistance, thereby enhancing public health surveillance of emerging strains. This development could potentially transform how complex infections are diagnosed and treated, providing critical insights where they are needed most. The collaboration reflects a commitment to advancing molecular diagnostics, which could lead to more timely clinical decisions and improved healthcare outcomes.
What's Next?
The next steps involve the rollout of the updated workflow through an early access program by Q3-2026. Cepheid and Oxford Nanopore will continue to engage with the scientific community, showcasing their progress at ESCMID Global. The companies share a long-term ambition to deliver an end-to-end in vitro diagnostic solution for complex infectious diseases. As the partnership progresses, it is expected to broaden the transformative possibilities of genomic workflows to additional research labs, potentially leading to more widespread adoption and integration into clinical practice.
